Shao-Lee Lin - 03 May 2026 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Reporting relationship: CHIEF EXECUTIVE OFFICER, Director
Issuer ticker: CUE
Reported as of: 03 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 May 2026, 16:00:05 UTC
Prior SEC filing: 07 May 2026
Next SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Shao-Lee Lin

Key filing fact

Shao-Lee Lin filed Form 4 for Cue Biopharma, Inc. (CUE) on 07 May 2026.

Key facts

This page summarizes Shao-Lee Lin's Form 4 filing for Cue Biopharma, Inc. (CUE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 07 May 2026, 16:00.

Change

Previous filing in this sequence was filed on 07 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001725092 Primary reporting owner

Lin Shao-Lee

Relationship: CHIEF EXECUTIVE OFFICER, Director
Address: C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON
Signature: /s/ Shao-Lee Lin
Signature date: 07 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CUE transaction

Common Stock

Award

Transaction value
Shares: +327,537
Change %
Price: $0.000000^*
Shares after: 327,537
Date: 03 May 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CUE transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +655,074
Change %
Price: $0.000000^*
Shares after: 655,074
Date: 03 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 655,074
Exercise price: $30.42
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This stock option becomes exercisable in 48 equal monthly installments beginning on April 30, 2026.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .